Cytometry Part B: Clinical Cytometry最新文献

{"title":"Challenges and approaches in the diagnosis and differential diagnosis of atypical CLL: A response to 'Defining atypical CLL for reproducible diagnosis: Implications of the work by Wang et al.'","authors":"Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang","doi":"10.1002/cytob.70003","DOIUrl":"10.1002/cytob.70003","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"223-225"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining atypical chronic lymphocytic leukemia for reproducible diagnosis: implications of the work by Wang et al.","authors":"Marc Sorigue","doi":"10.1002/cyto.b.22262","DOIUrl":"10.1002/cyto.b.22262","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"221-222"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145376433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"What are we measuring?\" reconsidering the biological identity and clinical interpretation of malaria-derived particles.","authors":"Zhihao Lei","doi":"10.1002/cytob.70011","DOIUrl":"10.1002/cytob.70011","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"226-227"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine-123 assay: Lessons from a large monocentric cohort.","authors":"Lodoeva Oiuna, Varlamova Tatiana, Yukhacheva Daria, Vedmedskaia Viktoriia, Fadeeva Mariia, Kulakovskaya Elena, Malakhova Ekaterina, Musaeva Elvira, Samykina Elizaveta, Sozonova Tatiana, Glushkova Svetlana, Igonina Mariia, Russiyanov Andrey, Brilliantova Varvara, Alexenko Maxim, Vahliarskaya Svetlana, Raykina Elena, Rodina Yulia, Maschan Michael, Shcherbina Anna, Pershin Dmitry","doi":"10.1002/cytob.70014","DOIUrl":"10.1002/cytob.70014","url":null,"abstract":"<p><p>The dihydrorhodamine-123 flow cytometry (DHR FC) assay is used to diagnose chronic granulomatous disease (CGD). This study presents the experience of a single center with the DHR FC assay in a large cohort to evaluate its applications and limitations. A total of 179 subjects were included in the study for CGD diagnosis, X-linked CGD (X-CGD) carrier determination, and post-hematopoietic stem cell transplantation (HSCT) chimerism monitoring. We performed the DHR FC assay using a standardized protocol, with additional intracellular myeloperoxidase (MPO) staining for borderline cases. The DHR FC assay demonstrated high diagnostic accuracy. PMA stimulation detected 94% of CGD cases. E. coli stimulation identified all CGD cases, including atypical EROS-deficient (CYBC1) patients (4.3% of the cohort) who exhibited residual reactive oxygen species production (median SI PMA = 40 vs. E. coli = 24). Genetic confirmation revealed that 82% of CGD patients had X-CGD (CYBB), and 18% had autosomal recessive CGD (CYBA/NCF1/NCF2/CYBC1) forms. Borderline results were clarified by MPO staining, which diagnosed three MPO-deficient cases. The assay reliably identified 43 X-CGD carriers out of 45 suspected cases and showed a strong correlation with the real-time quantitative polymerase chain reaction for HSCT chimerism monitoring (r = 0.78, p < 0.0001). The DHR FC assay is a rapid and reliable diagnostic tool for CGD, providing results within hours. Its applications extend to X-CGD carrier detection and post-HSCT chimerism monitoring. Dual-stimulant protocols (PMA + E. coli) and MPO staining enhance diagnostic accuracy. These findings support the use of the DHR FC assay as a versatile and essential tool in CGD management.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"201-220"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood plasmablasts, a potential confounder in chronic lymphocytic leukemia measureable residual disease analysis.","authors":"Jessica M Hughes, Joo Y Song, Winston Y Lee, Alexey V Danilov, Matthew G Mei, Huiyan Ma, Parastou Tizro, Olga V Danilova, Lorinda A Soma","doi":"10.1002/cyto.b.22263","DOIUrl":"10.1002/cyto.b.22263","url":null,"abstract":"<p><p>Measurable residual disease (MRD) testing for chronic lymphocytic leukemia (CLL) is often done on peripheral blood (PB) since the concordance of results with bone marrow is high and testing is less invasive. When analyzing CLL MRD data, one must be aware of small, normal populations in the PB that may be mistaken for residual CLL cells. As part of our CLL MRD assay validation, PB samples were collected from 10 healthy donors and a 2-tube CLL MRD flow cytometry panel was stained for each donor using markers CD19, CD20, BAFF-R, kappa, lambda, CD5, CD200, CD23, CD38, CD81, ROR1, CD79b, CD43, and CD45. Additional markers were utilized to exclude T-cells, NK-cells, and myeloid cells from the analysis. Samples were acquired on the Navios EX flow cytometer, and the data were analyzed using FCS Express software. Once the test was implemented, CLL PB patient samples were monitored. All 10 PBs from healthy donors contained small populations of cells present in the lymphocyte gate which mimicked CLL cells in their expression of CD45, CD19, CD20, CD43 (both positive, although CLL cells showed dimmer positive expression), CD79b, and level of surface light chains, immunophenotypically compatible with plasmablasts. Clinical implementation of the CLL assay revealed 12 out of 77 (16%) CLL PB patient samples demonstrating a small population of plasmablasts. Plasmablasts normally exist in peripheral blood at levels detectable by flow cytometry MRD assays and may be a potential confounder in the identification of MRD in CLL.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"172-179"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel flow cytometry approach to quantify malaria-derived particles.","authors":"Attakorn Palasuwan, Kritsamon Sophondilok, Sumate Ampawong, Suttipat Srisutham, Egarit Noulsri, Duangdao Palasuwan","doi":"10.1002/cytob.70006","DOIUrl":"10.1002/cytob.70006","url":null,"abstract":"<p><p>Quantifying malarial parasite density is crucial for diagnosis and treatment in endemic areas. While Malaria-derived particles (MDPs) have been linked to malaria pathology, a direct quantification method for routine laboratory use remains unestablished. To address this, our study optimized a flow cytometry approach to enumerate MDPs per microliter of blood. Specimens were incubated with propidium iodide and red blood cell (RBC) lysis solution. The number of MDPs was quantified using a CytoFlex flow cytometer, size-standard beads, and counting beads. Electron microscopy was used to study the ultrastructures of the malarial parasites in the lysed RBC specimens. A significant increase in MDP levels was detected in blood samples from P. falciparum and P. vivax infections, but fewer than 1 particle/μL of MDPs were detected in the controls. The number of MDPs correlated with the percentage of infected red blood cells (iRBCs) obtained by manual counting (R² = 0.94). The dilution assay demonstrated a strong correlation between the measured and expected values of the MDPs. An electron microscopic study demonstrated that different stages of malarial parasites exist in lysed RBCs in the form of membrane-bound spherical cells. A positive association was established between parasite density and MDPs across both P. falciparum (R² = 0.94) and P. vivax (R² = 0.91) infections. We demonstrated the potential use of flow cytometry for determining the MDP concentration. The developed approach is reliable and straightforward for the diagnosis and treatment of patients with malarial parasite infection in routine laboratory settings.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"180-189"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematopathological profile of plasmacytoid dendritic cell proliferation associated with non-myeloid acute leukemia.","authors":"Xiaojin Cai, Yanyan Song, Weichao Fu, Xulin Lu, Jun Wang, Lihui Shi, Yan Liu, Yuanyuan Li, Chong Wang, Yin Shi, Jianfeng Yao, Gang An, Yujiao Jia, Yijun Song, Xiaojing Wang, Yan Zhang, Ying Wang, Qi Sun","doi":"10.1002/cyto.b.22251","DOIUrl":"10.1002/cyto.b.22251","url":null,"abstract":"<p><p>Two types of plasmacytoid dendritic cell (pDC) proliferation disease are acknowledged so far by the 5th edition of the World Health Organization Classification of Haematolymphoid Tumors: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature pDC proliferation associated with myeloid neoplasms (MPDCP) in which pDC is part of the malignant clone. We aim to investigate pDC proliferation associated with non-myeloid acute leukemia (AL). A retrospective analysis of all cases admitted in our center with a diagnosis of non-myeloid AL from September 2020 to April 2023 was performed to select cases with pDCs greater than 2% of bone marrow by flow cytometry (FCM). We conducted comprehensive analyses encompassing FCM immunophenotyping, histopathological examination, morphological assessment, cytogenetic studies, and molecular genetic profiling across all cases. Proliferation of pDCs was detected in 10 (0.88%) out of 1140 non-myeloid AL patients by FCM, including 4/944(0.42%) cases of B lymphoblastic leukemia (B-ALL), 3/95 (3.16%) cases of T lymphoblastic leukemia (T-ALL) and 3/101 (2.97%) cases of acute leukemia of ambiguous lineage (ALAL) (p = 0.009). The 4 cases of B-ALL were all Philadelphia Chromosome positive (Ph+). PDCs in 3 out of 10 patients expressed CD56 (37.5%), 8/10 expressed CD7 (80%), 9/10 expressed CD303 (90%), all expressed CD304 (100%), and 5 of 8 evaluable cases were positive for CD34 (62.5%). In cases in which pDCs expressed CD7 and/or CD56, the blast cells all expressed CD7 and/or CD56 as well; the pDCs in all B-ALL patients expressed CD19. FCM dot plot in 2 of the B-ALL-pDC showed a spectrum from blast cells to pDCs: CD303 and CD304 gradually emerged as CD34 disappeared. Among the 8 patients who underwent bone marrow biopsy, pDCs exhibited two distinct distribution patterns: pure interstitial infiltration in 6 cases (75%) and focal/scattered clusters against an interstitial background in 2 cases (25%). NRAS showed recurrent mutations at identical genomic positions. Each NRAS variant (c.35G>A and c.38G>T) was detected twice across three patients. FCM could effectively detect pDC proliferation in non-myeloid leukemia, which occurred at a significantly higher incidence in T-ALL and ALAL than in B-ALL. In B-ALL, it was associated with the Ph + subtype. PDCs and blast cells shared some lymphoid antigens that were uncommon in AML-pDC or BPDCN. In the bone marrow, pDCs were predominantly characterized by an interstitial infiltration pattern.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"190-200"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monocyte maturation pattern by flow cytometry expression of CD64, CD300e, and CD14 correlates to presence of myeloid neoplasm and helps identify blast equivalents in the setting of monocytic neoplasm.","authors":"Jenny Zhang, Jacob Kaplan, Elizabeth Courville","doi":"10.1002/cyto.b.22256","DOIUrl":"10.1002/cyto.b.22256","url":null,"abstract":"<p><p>CD300e is a marker of mature monocytes in flow cytometry; however, there is limited detailed information on staining patterns in conjunction with other monocyte markers. We evaluated the flow cytometric staining patterns of CD64, CD14, and CD300e in 12 negative and 33 positive peripheral blood specimens and 16 negative and 56 positive bone marrow specimens. The positive cases were involved by myeloid neoplasms (increased blasts and/or abnormal monocytes). Flow cytometry plots were reviewed for each case, the monocyte population was identified by bright CD64 expression, and the monocyte maturation pattern was visualized by CD14 versus CD300e plots. Peripheral blood and bone marrow differential counts were collected. A total of 39% (22/56) of the positive bone marrow cases showed a different maturation pattern from the negative bone marrow cases. Of the positive peripheral blood cases, 28/33 (85%) showed a CD14 by CD300e pattern different from that observed in the negative peripheral bloods. When the subset of bone marrow cases involved by monocytic neoplasms was evaluated, there was no significant difference between monocyte percentage by flow cytometry versus morphology and between blast plus promonocyte percentage by flow cytometry versus morphology. We conclude that isolation of monocytes by bright CD64 expression and low side-scatter and subsequent evaluation of the CD14/CD300e maturation pattern may help identify myeloid neoplasms. Quantification of CD64 + CD14- and/or CD64 + CD300e- cells by flow cytometry may aid blast/blast equivalent identification/quantification.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"149-159"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basophilic blast crisis of chronic myelogenous leukemia presenting de novo: Diagnostic contribution of flow cytometry.","authors":"Chen Glait Santar, Tanya Badelbayov, Dan Benisty, Ben-Zion Katz","doi":"10.1002/cyto.b.70033","DOIUrl":"https://doi.org/10.1002/cyto.b.70033","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMIP-001: A clinical 13-antibody, 12-color flow cytometry panel for optimized immunophenotyping of T/NK cells in human leukemia and lymphoma diagnostics","authors":"Nicole So,&nbsp;Sara Monaghan,&nbsp;Katelynn Davis,&nbsp;Grant Bullock,&nbsp;Wendy Shallenberger,&nbsp;Ahmad Al-Attar","doi":"10.1002/cytob.70015","DOIUrl":"10.1002/cytob.70015","url":null,"abstract":"<p>The objective of this 12-color/13-antibody single-tube panel is to assist in the diagnosis of T/NK-cell leukemias and lymphomas. In the clinical setting, the absence of a standardized T/NK-cell panel limits inter-laboratory data comparability, contributes to diagnostic variability, and results in redundant efforts across laboratories to design and validate panels for flow cytometry. Developing and promoting a panel that allows for rapid and fairly comprehensive labeling of surface T/NK-cell markers, including the anti-T-cell receptor β-chain constant region 1 (TRBC1) antibody, will streamline the workflow by establishing a standard immunophenotyping T/NK-cell panel for detecting neoplastic T/NK cells and lay the foundation for future COMIPs.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 2","pages":"73-76"},"PeriodicalIF":2.7,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cytob.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}